Charles Ab Boucher
Overview
Explore the profile of Charles Ab Boucher including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
72
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
van Vliet M, Hendrickson C, Nichols B, Boucher C, Peters R, van de Vijver D
J Int AIDS Soc
. 2019 Dec;
22(12):e25427.
PMID: 31855323
Introduction: Although pre-exposure prophylaxis (PrEP.) is an efficacious HIV prevention strategy, its preventive benefit has not been shown among young women in sub-Saharan Africa, likely due to non-adherence. Adherence may...
2.
Hankins C, Koulla-Shiro S, Kilmarx P, Ferrari G, Schechter M, Toure Kane C, et al.
Antivir Ther
. 2017 Apr;
22(2):179-184.
PMID: 28387654
The underpinning theme of the 2016 INTEREST Conference held in Yaoundé, Cameroon, 3-6 May 2016 was ending AIDS as a public health threat by 2030. Focused primarily on HIV treatment,...
3.
Rokx C, Richman D, Muller-Trutwin M, Silvestri G, Lunzen J, Khoo S, et al.
J Virus Erad
. 2016 Aug;
1(3):211-20.
PMID: 27482415
The Second European Round Table on the Future Management of HIV took place in Barcelona, 10-11 October 2014 and focused on the HIV-1 reservoir, strategies for HIV cure and primary...
4.
Theys K, Deforche K, Vercauteren J, Libin P, van de Vijver D, Albert J, et al.
Retrovirology
. 2012 Oct;
9:81.
PMID: 23031662
Background: The effect of drug resistance transmission on disease progression in the newly infected patient is not well understood. Major drug resistance mutations severely impair viral fitness in a drug...
5.
Schreuder I, van der Sande M, de Wit M, Bongaerts M, Boucher C, Croes E, et al.
Harm Reduct J
. 2010 Oct;
7:25.
PMID: 20977742
Background: Injecting drug users (IDU) remain an important population at risk for blood-borne infections such as human immunodeficiency virus (HIV), hepatitis B virus (HBV) and hepatitis C virus (HCV). In...
6.
van Dijk D, Ertaylan G, Boucher C, Sloot P
BMC Syst Biol
. 2010 Jul;
4:96.
PMID: 20633292
Background: The National Institute of Allergy and Infectious Diseases has launched the HIV-1 Human Protein Interaction Database in an effort to catalogue all published interactions between HIV-1 and human proteins....
7.
Nijhuis M, van Maarseveen N, Verheyen J, Boucher C
Curr Opin HIV AIDS
. 2009 Apr;
3(6):627-32.
PMID: 19373034
Purpose Of Review: Several alternative mechanisms that cause protease inhibitor resistance have been proposed. A summary of the proposed mechanisms and the status regarding their clinical relevance is given. Recent...
8.
Walmsley S, Cotte L, Rusconi S, Ward D, Hicks C, Meier U, et al.
AIDS
. 2007 Dec;
21(16):2245-8.
PMID: 18090054
Week 48 HIV-RNA treatment response to the protease inhibitor tipranavir co-administered with ritonavir was compared with that of lopinavir co-administered with ritonavir in patients whose baseline isolates had varying lopinavir...
9.
Wensing A, Boucher C, van Kasteren M, Van Dijken P, Geelen S, Juttmann J
AIDS
. 2006 Jun;
20(10):1465-7.
PMID: 16791028
No abstract available.